TL;DR
Findings identify Sparsomycin, Genistein-7-O-glucuronide, and Curculigoside-G as promising inhibitors targeting the YjfP catalytic triad.
Findings show that kaempferol is a viable lead compound for cholera toxin suppression and serve as the foundation for future antitoxin medication development and experimental validation.
Streptococcus pneumoniae is the major causative agent of community-acquired pneumonia, one of the main infectious diseases that causes inflammation in the alveoli and leads to significant morbidity and mortality across various age groups. Current treatments are challenged by multidrug-resistant strains of S. pneumoniae...
Klebsiella pneumoniae (KPn) has emerged as a major global health concern due to increasing antimicrobial resistance (AMR). The development of new antimicrobial agents is essential to address multidrug-resistant and emerging hypervirulent strains associated with increased morbidity and mortality worldwide. In this study...
The rapid spread of antimicrobial resistance, particularly among pathogens such as Staphylococcus aureus and Escherichia coli, highlights the urgent need for novel antibacterial agents with new mechanisms of action. The bacterial enoyl‐acyl carrier protein reductase (FabI), an essential enzyme in fatty acid biosynthesi...
In silico pharmacokinetics predict oral bioavailability, rule-of-five compliance, water solubility, and non-toxicity, highlighting Kuwanon D as a promising antibacterial lead.
Antimicrobial resistance remains difficult to control because many bacteria rely on DNA repair pathways that help them survive antibiotic stress. One of the key players in this response is the Mutation Frequency Decline protein (Mfd), a transcription repair coupling factor that supports mutagenesis and persistence. Tar...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
